COMBINATION OF TRANSARTERIAL CHEMOEMBOLIZATION AND THREE-DIMENSIONAL CONFORMAL RADIOTHERAPY FOR HEPATOCELLULAR CARCINOMA WITH INFERIOR VENA CAVA TUMOR THROMBUS

被引:115
作者
Koo, Ja Eun [1 ]
Kim, Jong Hoon [2 ]
Lim, Young-Suk [1 ]
Park, Soo Jung [1 ]
Won, Hyung Jin [3 ]
Sung, Kyu-Bo [3 ]
Suh, Dong Jin [1 ]
机构
[1] Univ Ulsan, Dept Gastroenterol, Coll Med, Asan Med Ctr, Seoul 138736, South Korea
[2] Univ Ulsan, Dept Radiat Oncol, Coll Med, Asan Med Ctr, Seoul 138736, South Korea
[3] Univ Ulsan, Dept Radiol, Coll Med, Asan Med Ctr, Seoul 138736, South Korea
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2010年 / 78卷 / 01期
关键词
Hepatocellular carcinoma; Inferior vena cava tumor thrombus; Radiotherapy; Transarterial chemoembolization; RADIATION-THERAPY; NATURAL-HISTORY; ONCOLOGY-GROUP; TOXICITY; RESECTION; INVASION; CRITERIA;
D O I
10.1016/j.ijrobp.2009.07.1730
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the effects of transarterial chemoembolization (TACE) and three-dimensional conformal radiotherapy (CRT) in patients with hepatocellular carcinoma (HCC) and inferior vena cava tumor thrombus (IVCTT). Methods and Materials: A total of 42 consecutive patients who underwent TACE and CRT (TACE+CRT group) for the treatment of HCC with IVCTT were prospectively enrolled from July 2004 to October 2006. As historical controls, 29 HCC patients with IVCTT who received TACE alone (TACE group) between July 2003 and June 2004 were included. CRT was designed to target only the IVCTT and to deliver a median total dose of 45 Gy (range, 28-50 Gy). Results: Most baseline characteristics of the two groups were similar (p > 0.05). The response and progression-free rates of IVCTT were significantly higher in the TACE+CRT group than in the TACE group (42.9% and 71.4% vs. 13.8% and 37.9%, respectively; p < 0.01 for both rates). Overall, patient survival was significantly higher in the TACE+CRT group than in the TACE group (p < 0.01), with a median survival time of 11.7 months and 4.7 months, respectively. Treatment with TACE+CRT (hazard ratio [HR] = 0.38; 95% confidence interval [CI], 0.20-0.71), progression of IVCTT (HR = 4.05; 95% CI, 2.00-8.21), Child-Pugh class B (HR = 3.44; 95% Cl, 1.79-6.61), and portal vein invasion (HR = 2.31; 95% CI, 1.19-4.50) were identified as independent predictors of mortality by multivariable analysis. Conclusions: The combination of TACE and CRT is more effective in the control of IVCTT associated with HCC and improves patient survival compared with TACE alone. (C) 2010 Elsevier Inc.
引用
收藏
页码:180 / 187
页数:8
相关论文
共 32 条
  • [1] Asahara T, 1999, HEPATO-GASTROENTEROL, V46, P1862
  • [2] Management of hepatoceullular carcinoma
    Bruix, J
    Sherman, M
    [J]. HEPATOLOGY, 2005, 42 (05) : 1208 - 1236
  • [3] Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
    Cheng, Ann-Lii
    Kang, Yoon-Koo
    Chen, Zhendong
    Tsao, Chao-Jung
    Qin, Shukui
    Kim, Jun Suk
    Luo, Rongcheng
    Feng, Jifeng
    Ye, Shenglong
    Yang, Tsai-Sheng
    Xu, Jianming
    Sun, Yan
    Liang, Houjie
    Liu, Jiwei
    Wang, Jiejun
    Tak, Won Young
    Pan, Hongming
    Burock, Karin
    Zou, Jessie
    Voliotis, Dimitris
    Guan, Zhongzhen
    [J]. LANCET ONCOLOGY, 2009, 10 (01) : 25 - 34
  • [4] Radiation-induced liver disease after radiotherapy for hepatocellular carcinoma: clinical manifestation and dosimetric description
    Cheng, JCH
    Wu, JK
    Huang, CM
    Huang, DY
    Cheng, SH
    Lin, YM
    Jian, JJ
    Yang, PS
    Chuang, VP
    Huang, AT
    [J]. RADIOTHERAPY AND ONCOLOGY, 2002, 63 (01) : 41 - 45
  • [5] Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with inferior vena cava and right atrial tumors
    Chern, M. C.
    Chuang, V. P.
    Cheng, T.
    Lin, Z. H.
    Lin, Y. M.
    [J]. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2008, 31 (04) : 735 - 744
  • [6] TOXICITY CRITERIA OF THE RADIATION-THERAPY ONCOLOGY GROUP (RTOG) AND THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC)
    COX, JD
    STETZ, J
    PAJAK, TF
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (05): : 1341 - 1346
  • [7] External beam radiation therapy for hepatocellular carcinoma: Potential of intensity-modulated and image-guided radiation therapy
    Fuss, M
    Salter, BJ
    Herman, TS
    Thomas, CR
    [J]. GASTROENTEROLOGY, 2004, 127 (05) : S206 - S217
  • [8] Radiation therapy for hepatocellular carcinoma - From palliation to cure
    Hawkins, MA
    Dawson, LA
    [J]. CANCER, 2006, 106 (08) : 1653 - 1663
  • [9] Three-dimensional conformal radiotherapy for the treatment of arteriovenous shunting in patients with hepatocellular carcinoma
    Hsu, H. C.
    Chen, T. Y.
    Chiu, K. W.
    Huang, E. Y.
    Leung, S. W.
    Huang, Y. J.
    Wang, C. Y.
    [J]. BRITISH JOURNAL OF RADIOLOGY, 2007, 80 (949) : 38 - 42
  • [10] Three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava invasion
    Igaki, Hiroshi
    Nakagawa, Keiichi
    Shiraishi, Kenshiro
    Shiina, Shuichiro
    Kokudo, Norihiro
    Terahara, Atsuro
    Yamashita, Hideomi
    Sasano, Nakashi
    Omata, Masao
    Ohtomo, Kuni
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (06) : 438 - 444